Swiss Biotechs May Get SPAC Listing Option Soon
SPACs could ‘jump start’ Switzerland’s stalled IPO market
Executive Summary
Although 2020 was the best year ever for Swiss biotech financing activities, no domestic IPOs were launched by the sector. But introducing the SPAC might change that.
You may also be interested in...
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Digital Health Start-Ups Continue To Be Attractive SPAC Targets
According to Rock Health, 52 health-care focused SPACs are looking for targets. This comes as blank check companies are facing rising scrutiny by regulators.
Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.